Results 171 to 180 of about 66,048 (291)
Incidence and Long‐Term Outcomes of Pouchitis in Ulcerative Colitis Patients
ABSTRACT Background Ileal pouch‐anal anastomosis (IPAA) is the preferred intervention for ulcerative colitis (UC) patients whose medical treatment fails. Acute severe ulcerative colitis (ASUC) can precipitate the need for urgent surgery, potentially influencing post‐IPAA outcomes.
Rosalina Bergstrøm+8 more
wiley +1 more source
The Non-Peptide MAS-R Agonist AVE0991 Alleviates Colitis Severity in Mice and Exhibits an Additive Effect with Azathioprine. [PDF]
Khajah MA, Hawai S, Barakat A.
europepmc +1 more source
Pancytopenia related to azathioprine in rheumatoid arthritis. [PDF]
M. E. C. Jeurissen+2 more
openalex +1 more source
Treatment of Neurogenic Voice Disorders
ABSTRACT This overview serves as a foundational resource for clinicians caring for neurologically complex patients presenting with voice complaints. Neurogenic voice disorders are diverse in their clinical presentations and therapeutic approaches. A thorough medical history, including family history, detailed laryngeal examination, voice assessments ...
Mausumi Syamal
wiley +1 more source
Rituximab Therapy in Refractory Ocular Cicatricial Pemphigoid: A Case Report. [PDF]
Pauk SV+4 more
europepmc +1 more source
Outcomes of Fecal Diversion in Perianal Crohn's Disease: A Systematic Review and Meta‐Analysis
Fecal diversion provides symptom control in patients with perianal fistulising Crohn’s disease, with a 65% clinical improvement rate. However, bowel restoration is achieved in only 29% of cases, and many require re‐diversion or proctectomy/protocolectomy.
Imogen Hartley+4 more
wiley +1 more source
National guidelines for diagnosis, treatment, and management of myasthenia gravis in Israel. [PDF]
Shelly S+9 more
europepmc +1 more source
IMMUNOSUPPRESSION WITH AZATHIOPRINE, PREDNISONE, AND CYCLOPHOSPHAMIDE1
John Jeffery+3 more
openalex +1 more source
ABSTRACT Background/Objectives Janus kinase inhibitors (JAKis) have been approved by the Therapeutic Goods Administration for severe alopecia areata (AA) in Australia. However, access is limited as JAKis are not currently subsidised on the Pharmaceutical Benefits Scheme for this indication. This study aimed to establish expert consensus on criteria for
Meryl Thomas+23 more
wiley +1 more source